Nautilus Biotechnology (NASDAQ: NAUT) insider transactions
In the twelve months to 10 November 2026, executives and directors of Nautilus Biotechnology reported 2 open-market sales of 5,000,000 shares ($11.8m) and 1 open-market purchase of 25,000 shares ($65,250), by 2 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 2 June 2026 | AH Bio Fund II, L.P. | — | Open-market sale | −4,615,974 | $2.35 | 11,682,032 | Form 4 |
| 2 June 2026 | AH Bio Fund II, L.P. | — | Open-market sale | −384,026 | $2.35 | 971,885 | Form 4 |
| 4 March 2026 | Patel Sujal M | CEO, President, and Secretary | Open-market purchase | +25,000 | $2.61 | 10,366,721 | Form 4 |
| 6 November 2025 | Suzuki Kentaro | Chief Marketing Officer | Open-market purchase | +4,000 | $1.49 | 4,000 | Form 4 |
| 8 September 2025 | Patel Sujal M | CEO, President, and Secretary | Open-market purchase | +83,500 | $0.68 | 10,341,721 | Form 4 |
| 5 September 2025 | Patel Sujal M | CEO, President, and Secretary | Open-market purchase | +116,500 | $0.67 | 10,258,221 | Form 4 |
| 4 September 2025 | Murphy Matthew B. | General Counsel | Open-market purchase | +20,000 | $0.64 | 74,140 | Form 4 |
| 29 May 2025 | Mowry Anna | CFO and Treasurer | Open-market purchase | +15,000 | $0.77 | 83,000 | Form 4 |
| 12 May 2025 | Mallick Parag | Chief Scientist | Open-market purchase | +1,500 | $0.73 | 20,493,392 | Form 4 |
| 8 May 2025 | Mallick Parag | Chief Scientist | Open-market purchase | +12,000 | $0.73 | 20,491,892 | Form 4 |
| 20 March 2025 | Patel Sujal M | CEO, President, and Secretary | Open-market purchase | +23,933 | $1.00 | 10,141,721 | Form 4 |
| 19 March 2025 | Patel Sujal M | CEO, President, and Secretary | Open-market purchase | +53,300 | $0.99 | 10,117,788 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Nautilus Biotechnology page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.